Abstract
Adoptive T-cell immunotherapy is gaining credibility and popularity as a potential tool to cure cancer. Genetic engineering utilization of this therapeutic mode currently comes in the forms of chimeric antigen receptor- and T-cell receptor-engineered T cells. This short review focuses on opportunities to use engineered T cells to treat viral hepatitis-associated hepatocellular carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 43-49 |
| Number of pages | 7 |
| Journal | AIMS, Allergy and Immunology |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 19 Jul 2017 |
Keywords
- adoptive T-cell immunotherapy
- chimeric antigen receptor
- T-cell receptor
- viral hepatitis
- hepatocellular carcinoma
